Search Results

Locus Biosciences, Inc. today announced the release of $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli) based on positive results from a Phase 2a clinical trial.

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus Walk RNA Innovation Conference, held virtually.

Locus Biosciences, Inc. today announced that it completed a $35 million financing which included a Series B equity financing and conversion of an earlier convertible note.

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.

CosmosID® today announced a partnership for long-term support for Locus’ clinical trial initiatives.